Sun Pharma Advanced Research Company Limited — Updates, 24-02-2026: General Updates
24-02-2026 | 03:00 pm
24-02-2026 | 03:00 pm
SPARC clarified its valuation report following an NSE query, explaining why income-based valuation (DCF) is unsuitable. This is due to its R&D business, consistent losses, and lack of predictable revenue streams, making future projections difficult.
No comments yet. Be the first to comment!
All announcements from Sun Pharma Advanced Research Company Limited
